Jason Harris

Danielle Brander, MD, highlights how recent advances are changing the field of chronic lymphocytic leukemia and what it means for patients and their oncologists.

Andre Goy, MD, discusses some of the most important lymphoma data presented at the 2018 ASCO Annual Meeting and potential future directions for treatment.

The FDA approved filgrastim-aafi (Nivestym), a filgrastim (Neupogen) biosimilar, to prevent and treat side effects associated with cancer treatment, including febrile neutropenia and severe neutropenia.

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.

A review of available evidence has led the American Society for Radiation Oncology to issue a strong recommendation for use of concurrent chemotherapy with thoracic external beam radiation therapy in a subset of patients with incurable stage III non–small cell lung cancer.

An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling inhibitors.

Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.

Santhosh A. Upadhyaya, MD, discusses how chemotherapy prior to radiation can improve cure rates, the importance of long-term follow-up in this patient population, and emerging research and treatment for pediatric ependymoma.

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

The combination of the CDK4/6 inhibitor palbociclib and cetuximab induced an overall response rate of 39% in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.

New breast cancer screening guidelines from the American College of Radiology and Society of Breast Imaging advise all women to undergo risk assessment at age 30, followed by screening for those with a greater chance of cancer.

A new American Society for Radiation Oncology guideline calls for hypofractionated whole breast irradiation for patients with breast cancer regardless of age, tumor stage, and previous chemotherapy treatment.

Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.

The HER2-targeting antibody-drug conjugate (vic-)trastuzumab duocarmazine (SYD985) showed promising clinical activity in heavily-pretreated women with metastatic breast cancer.

The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.

Diane Reidy-Lagunes, MD, outlines the current state-of-the-art gastrointestinal care.

There are pivotal developments in colorectal cancer that have shaped the National Comprehensive Cancer Network guidelines in the past several years.

The FDA has expanded the indication for the Orbis Paxman Hair Loss Cooling System to prevent chemotherapy-related alopecia in patients with solid tumors.

Tucatinib used in combination with capecitabine, trastuzumab, or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases.

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

Sunitinib alone was noninferior to cytoreductive nephrectomy plus sunitinib, the current standard of care, in patients with synchronous metastatic renal cell carcinoma.

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

Evaluating health-related concerns as part of routine care for elderly patients with advanced cancer significantly improved doctor-patient communication and patient satisfaction.

A number of biological factors, including age at diagnosis, symptom duration at diagnosis, and HIST1H3B mutation status, are associated with survival ≥2 years in children and young adults with diffuse intrinsic pontine glioma, a brainstem malignancy with a median survival

The Cancer Genome Atlas Research Network has completed an integrative molecular analysis of roughly 10,000 tumor specimens and identified cancer subtypes that reflect shared molecular characteristics across traditional anatomic boundaries.

An underlying autoimmune condition may have played a role in making a 13-year-old patient refractory to treatment for immune thrombocytopenia.